Sara M. Tolaney
Harvard University(US)Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer(2021)1,444 cited
- → ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer(2021)1,286 cited
- → Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors(2017)1,061 cited
- → Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens(2017)1,039 cited
- → Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)(2014)1,015 cited
- → BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer(2005)989 cited